Akums Drugs and Pharmaceuticals Limited — Investor Meet, 11-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: In Q3 FY25, Akums Drugs & Pharmaceuticals reported consolidated total income of INR 1,025 crores, a decrease of 2% quarter-on-quarter and 6% year-over-year. Adjusted EBITDA reached INR 136 crores (up 1% QoQ, and 12% YoY), while profit after tax (PAT) was INR 66 crores, steady compared to Q2 and significantly up from INR 57 crores in Q3 last year. The API segment continues to face pricing pressures, but notable improvements were seen in the CDMO segment with margins advancing to 15.4%.

2. **Future Outlook and Growth Drivers**: Management is focusing on establishing a strong global CDMO footprint, highlighted by a recently secured EUR 200 million contract for supply to European markets, set to commence in 2027. The company has committed INR 32 crores towards enhancing R&D capabilities to support product development in regulated markets.

3. **Order Book and Operational Updates**: The company's order book remains robust with expectations of continued volume growth driven by various contracts. Q3 saw only a 0.6% volume increase QoQ in the CDMO segment, though future projections remain optimistic for Q4 and beyond.

4. **Analyst Q&A Insights (Detailed)**:

- **Revenue and Profitability**: Analysts probed the decline in revenue, attributed to falling API prices. Management emphasized the strategic decision to focus on higher-margin products and rationalize the API portfolio.

- **Market Position and Competitive Landscape**: Akums retains over 30% market share in India-focused CDMO, serving a diverse customer base, including major multinationals.

- **Operational Challenges or Risks**: Management acknowledged challenges in the API segment but expressed confidence in ongoing R&D efforts to pivot towards higher margin products and exports.

- **Capex and Capital Allocation**: Future capex is projected at INR 175-200 crores annually, primarily for commissioning new plants and production lines.

- **Strategic Priorities and Long-Term Vision**: Management highlighted the aim to enhance margins and expand market share through innovation and strategic partnerships.

5. **Market or Regulatory Updates**: While specifics on regulatory matters were not discussed, there is a consistent emphasis on expanding into regulated markets as part of the overall growth strategy.

6. **Strategic Focus Areas**: Key areas include enhancing product offerings through R&D, expanding manufacturing capabilities, and solidifying partnerships in both domestic and international markets, indicating a proactive approach to drive growth.

7. **Investor Insight**: Given the promising financial health and strategic direction towards profitability and market expansion, the outlook suggests a favorable position, leaning towards a ‘buy’ stance for investors looking at long-term growth potential. However, the API pricing challenges and current capacity underutilization necessitate close monitoring for sustained performance.